Compare STSS & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STSS | IXHL |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | Australia |
| Employees | 55 | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 37.0M |
| IPO Year | N/A | 2024 |
| Metric | STSS | IXHL |
|---|---|---|
| Price | $1.84 | $3.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 169.6K | ★ 249.3K |
| Earning Date | 04-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.16 |
| 52 Week High | $18.23 | $6.39 |
| Indicator | STSS | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 55.48 |
| Support Level | $1.66 | $0.33 |
| Resistance Level | $2.00 | $5.08 |
| Average True Range (ATR) | 0.11 | 0.35 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 25.00 | 74.14 |
Sharps Technology Inc is a medical device and pharmaceutical packaging company offering patented, smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities that incorporate syringe technologies that use both passive and active safety features. The Company has adopted a digital asset treasury scheme focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.